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Introduction
Bone remodeling involves bone resorption by osteoclasts
and subsequent formation of new bone by osteoblasts1-3. This
process regulates the biomechanical features of bone and
maintains the homeostasis of essential mineral ions in the
body1. Alteration in the bone remodeling process results in dis-
eases such as osteoporosis that can often cause life-threatening
complications3. The mechanisms regulating bone remodeling
are not fully understood, and unveiling them should eventually
allow development of new therapeutic approaches for osteo-
porosis and other bone related diseases3. 
The process of bone formation and resorption is well-regu-
lated, at least, at two different levels: locally and centrally1. Lo-
cally, bone remodeling is regulated through direct interaction
between osteoblasts and osteoclasts, and by local interactions
between cells of the immune system and bone cells1. Centrally,
bone remodeling has been shown to be regulated at three axis:
1) the hypothalamic-pituitary-thyroid axis; 2) the co-regulation
of bone, adipose tissue and energy metabolism mediated by the
sympathetic nervous system (SNS) and 3) the IL 1- parasym-
pathetic nervous system (PSNS)- bone axis4-11. The last two
axes are mediated by adrenergic and cholinergic activities, the
functional arms of autonomic nervous system4-11.
The adrenergic activity of the SNS has been shown to be a
negative regulator of bone mass; adrenergic signaling inhibits
osteoblast proliferation and promotes osteoclastogenesis4-6,12.
Moreover, SNS signaling induces the release of the osteoblast-
derived soluble factor receptor activator of NF-κB ligand
(RANKL), which in turn augments osteoclastogenesis and
bone resorption6. SNS signaling are well controlled by the ac-
tion of two key proteins: osteocalcin and leptin. Osteocalcin,
produced by mature osteoblasts and osteocytes, regulates the
production of leptin, an adipocyte-derived hormone. Leptin,
in-turn, activates its receptors in the hypothalamus and pro-
motes SNS activity4-6.
Cholinergic activity has been shown to favor bone mass by
increasing osteoblast proliferation via suppression of the SNS
and promoting the apoptosis of osteoclasts10,11. The present ar-
ticle reviews the current understanding of the cholinergic effect
on bone remodeling based on a variety of in vitro, in vivo and
clinical studies, and suggests new ways for preventing bone
fractures and osteoporosis by cholinergic stimulation.
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Abstract
Bone remodeling is regulated by the two branches of the autonomic nervous system: the adrenergic and the cholinergic branches.
Adrenergic activity favors bone loss, whereas cholinergic activity has been recently shown to favor bone mass accrual. In vitro
studies have reported that cholinergic activity induces proliferation and differentiation of bone cells. In vivo studies have shown
that the inhibition of cholinergic activity favors bone loss, whereas its stimulation favors bone mass accrual. Clinical studies have
shown that bone density is associated with the function of many cholinergic-regulated tissues such as the hypothalamus, salivary
glands, lacrimal glands and langerhans cells, suggesting a common mechanism of control. Altogether, these observations and
linked findings are of great significance since they improve our understanding of bone physiology. These discoveries have been
successfully used recently to investigate new promising therapies for bone diseases based on cholinergic stimulation. Here, we
review the current understanding of the cholinergic activity and its association with bone health.
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Cholinergic system
Cholinergic system regulates the body’s metabolic activity
through the use of acetylcholine as a signal transmitter13.
Acetylcholine is biosynthesized by choline acetyl transferase,
and it is stored in small synaptic vesicles through the action of
vesicular acetylcholine transporter enzyme to be released via
exocytosis into the synapse space14. The secreted acetylcholine
targets either nicotinic or muscarinic receptors15,16. Nicotinic
receptors are compromised of different subunits α, β, γ, δ and
ε that assemble to form ionic channels17. Muscarinic receptors
are guanine nucleotide protein coupled receptors, and are clas-
sified into five subtypes: m1, m2, m3, m4 and m516,18. Acetyl-
choline signal is terminated by its degradation through the
enzyme acetylcholinesterase (AChE)19. 
Many neuronal cells such as all pre- and post-ganglionic
nerves of the PSNS, preganglionic and some postganglionic
nerves of the SNS, motor neurons and neurons within the cen-
tral nervous system express the components of the cholinergic
system (transmitter, enzymes and receptors)10,11,20-22. Moreover,
many non-neuronal cells such as embryonic stem cells, epithe-
lial cells and bone cells have been shown to express compo-
nents of the cholinergic system as well13,23,24.
Expression of cholinergic components in bone
Bone cells have been shown to express several components
of the cholinergic system (transmitter, enzymes and recep-
tors)10,11,15,16,25-30. For instance, acetylcholine has been sug-
gested to be produced by osteosblasts due to the presence of
the vesicular acetylcholine transporter enzyme in these cells30.
Cholinergic receptors, both nicotinic and muscarinic, have
been identified on the membranes of human primary bone
cells, mesenchymal stem cells, osteoblasts and osteo-
clasts10,11,25,26,31-34. The mRNA of several nicotinic receptors
subtypes (α1, α4, b1 and g) are also present in osteocytes
35.
AChE is expressed in bone cells such as bone marrow-derived
monocytes, osteoclasts and osteoblasts11,29,36. 
Possible role of cholinergic components in bone
The wide expression of cholinergic components in bone tis-
sue points toward the important role they could play in bone
remodeling23. Previous studies have shown that acetylcholine
might regulate the migration of bone marrow-derived multi-
progenitor mesenchymal stem cell37 capable of differentiating
into bone cells. Both families of cholinergic receptors, nico-
tinic and muscarinic, have been shown to affect bone turnover.
Indeed, nicotinic stimulation in mice induces bone mass gain
as a result of an increase in osteoclasts apoptosis11, whereas
muscarinic stimulation in vitro increases osteoblasts prolifer-
ation25,30. Among the cholinergic receptors, the nicotinic sub-
type-α2 receptor and muscarinic-3 receptor appear important
in bone physiology10,11,38-40. Indeed, mice with knockout nico-
tinic subtype-α2 receptors are osteoporotic due to the up-reg-
ulation of osteoclasts11, whereas mice with knockout
muscarinic-3 receptors are osteoporotic due to a decrease of
osteoblast numbers and an increase of osteoclast numbers10. 
Beside its capability to break down acetylcholine, AChE is
thought to play significant roles during remodeling of bone.
For instance, AChE has been detected at the sites of new bone
formation36, suggesting a role for AChE as a bone matrix pro-
tein29,36. Moreover, it has been reported that AChE can regulate
bone cells proliferations, differentiations, cell-cell contact as
well as mesenchymal stem cells migration27,29,36,41,42.
Cholinergic innervation of bone
It has been shown that bone tissues are innervated by cholin-
ergic fibers of both the PSNS and the SNS11,43. Cholinergic
fibers transmit neuronal signaling from the PSNS nucleus
within the CNS to cholinergic receptors located in bone11. Ac-
cordingly, it would be logical to expect that disruption in the
function of these cholinergic fibers would affect bone. Indeed,
it has been shown that mice subjected to subdiaphragmatic sec-
tioning of the vagus nerve, a cranial nerve that caries cholin-
ergic fibers of the PSNS, suffer from low bone mass in their
lumbar vertebra44. Cholinergic fibers of the SNS have been
shown to innervate the periosteum, a connective tissue that
covers the bone and contains progenitor cells that develop into
osteoblasts, indicating a possible role of these neuronal fibers
in regulating bone formation and remodeling45. Indeed, den-
ervation of the periosteum results in poor bone healing in an-
imal models, indicating that periosteal nerves are required for
bone formation and fracture healing46-49. 
Central nervous system nuclei 
Hypothalamus
Previous studies have shown that the hypothalamus, a brain
structure that encloses cholinergic (muscarinic and nicotinic)
and adrenergic components, can affect bone remodeling50,51. It
has been shown that Alzheimer’s disease (AD) patients suffer-
ing from cholinergic degradation of the hypothalamus52,53, are
more prone to develop osteoporosis and suffer from a high in-
cidence of fractures54-57. In fact, the association between bone
mineral density and cholinergic degradation of the hypothala-
mus is so strong58,59 that decrease in bone mineral density has
been suggested as a predictor of AD60. These observations
highlight the importance of cholinergic nucleus of the hypo-
thalamus in regulating bone mass accrual.
One mechanism by which the hypothalamus might regulate
bone remodeling is by controlling body weight4, a known pos-
itive regulator of bone mass61,62. The hypothalamus encloses
two structures that regulate body weight: the ventromedial and
the lateral hypothalamic nuclei. The lateral hypothalamic nu-
cleus is concerned in hunger, and any damage to this area can
reduce body weight63. Lateral hypothalamic nucleus is known
to enclose cholinergic neurons and receptors, such as mus-
carinic receptors10,64. Accordingly, suppression of cholinergic
neurons activity in the lateral hypothalamic nucleus could ex-
plain why AD patients usually suffer from weight loss, hence
low bone mass accrual65. However, future research has to be
done to test these hypotheses.
It is well known that the hypothalamus regulate bone mass
also through a neurohormonal pathway mediated by the pitu-
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itary-thyroid-bone axis5,8. It has been reported that the expres-
sion of muscarinic receptors centrally might be regulated by
the level of calcitonin66, a hormone that plays a significant role
in the pituitary-thyroid- bone axis. However, it has not been
investigated whether this association between muscarinic re-
ceptors and calcitonin would affect bone mass.
Locus coeruleus
Muscarinic receptors, more specifically muscarinic-3 recep-
tors, are expressed in non-adrenergic neurons in the locus
coeruleus nucleus, a brain structure necessary for the SNS10.
It has been shown that mice with knockout neural muscarinic-
3 receptors are osteoporotic due to an increase in SNS signal-
ing, indicating that muscarinic-3 receptors in the locus
coeruleus nucleus down-regulate SNS signaling and favor
bone mass indirectly10. 
Central IL-1
Central IL-1 is a proinflammatory cytokine produced by
brain neurons that are known to regulate learning, memory and
sleep patterns67,68. Central IL-1 can also affect bone metabo-
lism through nicotinic nerve fibers of the PSNS11. Indeed, mice
with knockout central IL-1 express very low levels of skeletal
acetylcholine11, and these mice are osteoporotic due to the de-
crease of apoptosis in osteoclasts11,69. 
Pathways by which the cholinergic system regulates 
bone remodeling
Despite the substantial evidences we presented regarding the
association between cholinergic activities at bone tissues-, neu-
rons- and nuclei-level with bone remodeling, the pathways by
which the cholinergic system affects bone remodeling are not well
understood. It is still not known whether the cholinergic activity
affects bone cells locally, systemically or both. In Figure 1, we
suggest possible mechanisms for cholinergic regulation of bone.
Recent studies have shown that cholinergic activity might regulate
Body tissue that expresses Function of local Effect of inhibition of Association between local inhibition 
cholinergic receptors cholinergic receptors local cholinergic receptors of cholinergic receptors and bone 
mineral density (BMD)
Salivary glands70 Saliva secretion78 Dry mouth78 Patients with dry mouth are associated
with low BMD81
Lacrimal glands72 Lacrimal secretion114 Dry eyes79 Patients with dry eyes are associated 
with low BMD82
Pancreas73 Insulin secretion115 Diabetes type180,116 Patients with diabetes type 1 are 
associated with low BMD83,84,117,118
Respiratory system119 Smooth muscle contraction Obstructive pulmonary Patients with lung diseases are 
and epithelial regulation119,120 disease88 associated with low BMD85
Gastrointestinal system74 Smooth muscle contraction74 Decrease muscle tone121 Patients with gastrointestinal diseases 
are associated with low BMD89
Vestibular organ within ear76 Regulate balance and Unbalance and disorientation Patients with vertigo are associated 
orientation122 (Vertigo) with low BMD92
Table 1. The relationship between cholinergic receptors in body tissues with bone turnover in various clinical conditions.
Figure 1. Model of the autonomic nervous system-mediated regulation
of bone mass accrual. The SNS favors bone loss by inhibiting os-
teoblast proliferation, directly by activating the adrenergic receptors.
Also, the SNS favors bone loss by promoting osteoclast proliferation,
directly through activating the adrenergic receptors on osteoclasts and
indirectly through stimulating RANKL secretion from osteoblasts. The
PNS favors bone mass indirectly by suppressing the SNS signaling
and directly by promoting apoptosis in osteoclasts through activating
the nicotinic receptors. The two blue-dashed arrows refer to possible
effects of the PNS on osteoblasts and osteocytes.
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Cholinergic activity regulates many organs in which cholin-
ergic receptors have been identified such as: salivary cells,
lacrimal cells, langerhans cells, the respiratory system, the gas-
trointestinal system and the vestibular organ within the ear
(Table 1)24,70-77. Decrease cholinergic activity in salivary glands
function results in a dry mouth (xerostomia)78. Similarly, sup-
pression of cholinergic activity in lacrimal glands results in
dry eyes79. Damage to muscarinic-3 receptors in langerhans
cells result in diabetes type 180. Surprisingly, several articles
in the literature have reported strong association of an un-
known etiology between these medical conditions (xerostomia,
dry eyes and diabetes type 1) and bone loss81-84. However, the
evidence we present in this study seems to indicate that bone
loss in these medical conditions could be due to alterations in
cholinergic activity. 
Suppression of cholinergic activity is also known to cause
the onset of serious pathologies such as obstructive pulmonary
diseases, disruption in the body’s circadian rhythm and learn-
ing memory deficits85-88. Interestingly, all these conditions have
as a common skeletal feature, a reduction in bone mineral den-
sity85,89,90. Another interesting condition which is associated
with cholinergic activity is vertigo. Vertigo patients are char-
acterized by dizziness and being off-balanced as a conse-
quence of a damage to the vestibular end organ in the ear91, a
cholinergic-regulated organ76. Patients suffering from vertigo
are associated with higher risk of osteoporosis92. 
Circadian rhythm
An interesting phenomenon that links cholinergic activity
with bone remodeling is the circadian rhythm. The autonomic
nervous system follows a circadian pattern that matches the
bone remodeling cycle. Sympathetic activity is dominant dur-
ing day hours when bone resorption activity reaches its peak,
while the parasympathetic activity is intense during night
hours when bone formation is more active93,94. 
Menopause
Another observation that links cholinergic activity to bone
is the estrogen replacement therapy, a hormonal treatment for
osteoporosis. Patients under estrogen replacement therapy are
well known to have high bone mass and low fractures risk95.
Surprisingly, these patients express an increase in cholinergic
activity96. 
Smokers
Clinical studies have shown that heavy smoking is associ-
ated with a decreased bone mass and diminished fracture heal-
ing capacity31,97,98,99. Even though many hypotheses have been
postulated to explain this phenomena, it has been found that
the association between smoking and bone is strongly related
to nicotine levels in the body100. Even though low concentra-
tion of nicotine up-regulates osteoblasts through activation of
the nicotinic receptors32,39, excesive levels down-regulate os-
teoblasts through desentistizating their nicotinic receptors38.
Also excesive nicotinic levels up-regulate osteoclasts through
activation of the niotinic receptors11. 
Poliomyelitis, Botox injection and Myasthenia gravis 
Cholinergic neurons innervate muscle fibers101, and their ac-
tivity can affect bone mass through mechanical stress102. In-
deed, it has been argued whether the muscle activity, rather
than the neuronal activity, is the main regulator of bone mass.
However, the following observations argue strongly against a
model whereby the muscle activity is more important than neu-
ronal activity in regulating bone mass. Underneath, we discuss
how three conditions, known to affect neuro-muscular
synapses: Poliomyelitis, Botox injections and Myasthenia
gravis, affect bone health status
Poliomyelitis is a viral disease that destroys motor neurons
that utilize acetylcholine neurotransmitter resulting in muscle
paralysis103. Patients diagnosed with poliomyelitis are known
to suffer from impaired bone growth affected by nerve deple-
tion104. Interestingly, it has been found that after recovery of
muscle activity, polio patients tend to develop osteoporosis in
a much larger proportion than the rest of the population, indi-
cating that the effect of polio virus on bone tissue is unrelated
to muscle function104. 
Botox, known as botulinum neurotoxin, prevents the release
of acetylcholine from its membrane vesicles at the terminal
ends of cholinergic neurons resulting in muscle paralysis105.
Botulinum neurotoxin causes bone loss that does not improve
following the recovery of muscle function106,107. Moreover,
bone loss due to botulinum neurotoxin has been associated
with an increase in bone resorption due to osteoclasts up-reg-
ulation106, a phenomena that is recently linked to the inhibited
activity of cholinergic fibers of the PSNS11. Accordingly, these
findings indicate that the effect of botulinum neurotoxin on
bone tissue is unrelated to muscle function.
Myasthenia gravis is a disorder that is characterized with
suppressed muscular activity due to autoantibodies blocking
the cholinergic receptors in muscle fibers. Surprisingly, despite
the low muscular activity, patients diagnosed with Myasthenia
graves are not associated with the risk of developing bone dis-
ases108-110. In contrast, Myasthenia gravis patients are more re-
sistant to develop osteoporosis compared to general
population109. Myasthenia gravis only affects acetylcholine re-
ceptors in muscles leaving cholinergic signaling in bone intact,
which might explain why bone is not affected in these patients. 
The linking findings described for the above three condi-
tions indicated that cholinergic innervation is necessary and
might be more important than muscle activity for healthy bone
remodeling. However, future studies will have to be performed
in order to confirm the role of cholinergic activity in defining
the bone phenotype of patients with Poliomyelitis, Myasthenia
graves or following Botox injections.
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Future therapies for osteoporosis
The available literature indicates that the inhibition of
cholinergic activity at the bone level and in the central nervous
system reduces bone mass10,11,40. This has lead researchers to
investigate whether boosting acetylcholine activity might have
an anabolic effect on bone formation.
One way of stimulating cholinergic receptors is by the ad-
ministration of cholinergic agonists such as acetylcholinesterase
inhibitors (AChEIs). AChEIs are a group of drugs that cause
stimulation of cholinergic receptors (nicotinic and/or mus-
carinic) by inhibiting the action of AChE and increasing the lev-
els of acetylcholine in the synaptic space. A recent study has
revealed that the use of pyridostigmine, a peripherally acting
AChEI that stimulates nicotinic receptors, favors bone mass in
animal models by stimulating osteoclast apoptosis11. Another re-
cent clinical study reported that treatment with centrally acting
AChEI that stimulates both nicotinic and muscarinic receptors
such as donepezil and rivastigmine was associated with lower
risk of hip fracture in Alzheimer’s disease patients111. In the same
study, it was shown that centrally acting AChEI that stimulates
nicotinic receptors only such as galantamine had no beneficial
effect in lowering the risk of hip fracture111. Accordingly, it
seems that stimulating cholinergic receptors through pharmaco-
logical approaches could favor bone mass. These findings open
the window for a new therapeutic approach to treat osteoporosis
through stimulation of the cholinergic system. 
Future studies
Even though there is substantial evidence in the literature
indicating the importance of cholinergic activity on bone, there
is however still much to learn about the complicated relation-
ships between the cholinergic system and bone. For instance,
future studies will have to be performed in order to investigate
whether the cholinergic activity affects bone mass by other
mechanism rather than the IL 1-PSNS-bone and Locus
coeruleus-SNS-bone pathways. The interaction between the
cholinergic system with endocrine system, and the effects of
this interaction on bone mass need to be investigated.
Another area that needs investigation is the possible in-
volvement of nicotinic receptors expressed by osteocytes. It is
well known that osteocytes can suppress osteoblast prolifera-
tion through the secretion of sclerostin, an inhibitor of the Wnt
signaling pathway in osteoblasts, and promote osteoclast pro-
liferation directly through RANKL secretion112,113. Accord-
ingly, nicotinic receptors in osteocytes could be mediating the
interactions between these cells with osteoblasts and osteo-
clasts, although future studies will have to be performed to ad-
dress this hypothesis. 
Conclusion
In this review we have summarized several observations
demonstrating that the cholinergic signaling is a positive reg-
ulator of bone mass. In vitro studies have suggested that acetyl-
choline might regulate proliferation and differentiation of bone
cells. In vivo studies have shown that altering cholinergic ac-
tivity regulates bone mass accrual. Clinical studies have shown
that diseases caused by disruption of cholinergic activity seem
to be associated with bone disorders. Even though we here pre-
sented substantial evidence from the literature indicating the
importance of cholinergic activity on bone, however there is
still much to learn about the complicated relationships between
the cholinergic system and bone.
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